Literature DB >> 20384778

Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain.

Devi Rani Sagar1, Maulik D Jhaveri, Denise Richardson, Roy A Gray, Eva de Lago, Javier Fernández-Ruiz, David A Barrett, David A Kendall, Victoria Chapman.   

Abstract

Models of neuropathic pain are associated with elevated spinal levels of endocannabinoids (ECs) and altered expression of cannabinoid receptors on primary sensory afferents and post-synaptic cells in the spinal cord. We investigated the impact of these changes on the spinal processing of sensory inputs in a model of neuropathic pain. Extracellular single-unit recordings of spinal neurones were made in anaesthetized neuropathic and sham-operated rats. The effects of spinal administration of the cannabinoid CB(1) receptor antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251) and the cannabinoid receptor type 2 (CB(2)) receptor antagonist N-[(1S)-endo-1,3,3-trimethylbicycloheptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide (SR144528) on mechanically-evoked responses of spinal neurones were determined. The effects of spinal administration of (5Z,8Z11Z,14Z)-N-(3-furanylmethyl)-5,8,11,14-eicosatetraenamide (UCM707), which binds to CB(2) receptors and alters transport of ECs, on evoked responses of spinal neurones and spinal levels of ECs were also determined. The cannabinoid CB(1) receptor antagonist AM251, but not the CB(2) receptor antagonist, significantly facilitated 10-g-evoked responses of spinal neurones in neuropathic, but not sham-operated, rats. Spinal administration of UCM707 did not alter spinal levels of ECs but did significantly inhibit mechanically-evoked responses of neurones in neuropathic, but not sham-operated, rats. Pharmacological studies indicated that the selective inhibitory effects of spinal UCM707 in neuropathic rats were mediated by activation of spinal CB(2) receptors, as well as a contribution from transient receptor potential vanilloid 1 (TRPV1) channels. This work demonstrates that changes in the EC receptor system in the spinal cord of neuropathic rats influence the processing of sensory inputs, in particular low-weight inputs that drive allodynia, and indicates novel effects of drugs acting via multiple elements of this receptor system.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20384778     DOI: 10.1111/j.1460-9568.2010.07162.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  13 in total

1.  Centrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociception.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Pharmacol Biochem Behav       Date:  2011-09-17       Impact factor: 3.533

2.  Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon.

Authors:  Karen L G Farizatto; Sara A McEwan; Vinogran Naidoo; Spyros P Nikas; Vidyanand G Shukla; Michael F Almeida; Aaron Byrd; Heather Romine; David A Karanian; Alexandros Makriyannis; Ben A Bahr
Journal:  J Mol Neurosci       Date:  2017-08-12       Impact factor: 3.444

Review 3.  The cannabinoid system and pain.

Authors:  Stephen G Woodhams; Victoria Chapman; David P Finn; Andrea G Hohmann; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2017-06-15       Impact factor: 5.250

4.  The interaction between intrathecal administration of low doses of palmitoylethanolamide and AM251 in formalin-induced pain related behavior and spinal cord IL1-β expression in rats.

Authors:  Nima Naderi; Mohsen Majidi; Zahra Mousavi; Solaleh Khoramian Tusi; Zahra Mansouri; Fariba Khodagholi
Journal:  Neurochem Res       Date:  2011-12-27       Impact factor: 3.996

5.  A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity.

Authors:  Vinogran Naidoo; Spyros P Nikas; David A Karanian; Jeannie Hwang; Jianhong Zhao; JodiAnne T Wood; Shakiru O Alapafuja; Subramanian K Vadivel; David Butler; Alexandros Makriyannis; Ben A Bahr
Journal:  J Mol Neurosci       Date:  2010-11-11       Impact factor: 3.444

6.  Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors.

Authors:  Martin Kaczocha; Stephanie Vivieca; Jing Sun; Sherrye T Glaser; Dale G Deutsch
Journal:  J Biol Chem       Date:  2011-12-14       Impact factor: 5.157

Review 7.  On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence.

Authors:  Karen Jaqueline Paredes-Ruiz; Karla Chavira-Ramos; Mario Orozco-Morales; Cimen Karasu; Alexey A Tinkov; Michael Aschner; Abel Santamaría; Ana Laura Colín-González
Journal:  Neurotox Res       Date:  2021-11-06       Impact factor: 3.911

8.  Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.

Authors:  Farinaz Nasirinezhad; Stanislava Jergova; James P Pearson; Jacqueline Sagen
Journal:  Neuropharmacology       Date:  2014-12-05       Impact factor: 5.250

Review 9.  Dynamic changes to the endocannabinoid system in models of chronic pain.

Authors:  Devi Rani Sagar; James J Burston; Stephen G Woodhams; Victoria Chapman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

10.  Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies.

Authors:  David P Finn; Simon Haroutounian; Andrea G Hohmann; Elliot Krane; Nadia Soliman; Andrew S C Rice
Journal:  Pain       Date:  2021-07-01       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.